PolyNovo North America LLC
$2.0M 5,925 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Alimera Sciences, Inc.
Alimera Sciences, Inc. reported $1,956,782.76 across General Payments, Research, and Ownership to 3,868 physicians and teaching hospitals across 4,187 transactions.
- $2.0M Top quartile payer
- All-tracks total
- 4,187 Top quartile volume
- Transactions
- 3,868 Top quartile reach
- Recipients
- +$234.5K
- General Payments vs PY2023
Alimera Sciences, Inc. reported $1,956,782.76 across all CMS Open Payments tracks (General + Research + Ownership) to 3,868 physicians and teaching hospitals in Program Year 2024 - ranking #452 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $791,785.49, averaging $505.89 per recipient.
How Alimera Sciences, Inc.'s $2.0M all-tracks total breaks down
Alimera Sciences, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
36/100
Total payments
F
28/100
Transaction volume
F
40/100
Physician reach
F
39/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer alimera-sciences-inc Alimera Sciences, Inc.
$2.0M · #452/1,925 · 0.0% industry · PY2024
- TOT $2.0M
- RANK #452
- SHARE 0.0%
- TXN 4,187
- RCP 3,868
- CAT 3
- GEN $791.8K
- ΔGEN +$234.5K
- TOP1 10.0%
- PY 2024
Volume peers
Nearest volume peer: PolyNovo North America LLC ($2.0M)
Alimera Sciences, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Alimera Sciences, Inc.'s CMS-reported General Payments increased by $234.5K (+42.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ALIMERA SCIENCES, INC.PY2023: ALIMERA SCIENCES, INC.PY2024: Alimera Sciences, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $557,237.99
- PY2024
- $791,785.49
What the Data Shows for Alimera Sciences, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Alimera Sciences, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 3 general-payment categories charted below, "Honoraria" is the largest at $573.8K across 182 transactions, 72.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Honoraria" leads Alimera Sciences, Inc.'s 3-category general-payment breakdown at $573.8K, 72.5% of the reported total.
How Alimera Sciences, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $573.8K | 182 | 72.5% |
| Food and Beverage | $211.2K | 3,668 | 26.7% |
| Travel and Lodging | $6.8K | 18 | 0.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $238,479.36 (30.1%) of $791,785.49 in this company's General Payments records across 1,464 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Alimera Sciences, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Lisa Faia
$79,428.55 across 35 reported transactions
- 2
Mark Dacey
$66,928.73 across 25 reported transactions
- 3
Jorge Fortun
$38,854.00 across 10 reported transactions
- 4
Stephen Anesi
$28,213.96 across 24 reported transactions
- 5
Donald Mazzulla
$25,054.12 across 26 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Alimera Sciences, Inc. ranks #452 of 1,925 by total payments (top 23% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,470 of 1,838 by HHI (bottom 20% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Si-Bone, Inc. : $8.1M total payments, HHI 291
- Linde Gas & Equipment Inc. : $116.7K total payments, HHI 290
- Solventum Corporation : $6.0M total payments, HHI 289
- Enterra Medical, Inc. : $447.0K total payments, HHI 289
- Alcon Puerto Rico Inc : $5.0K total payments, HHI 288
- Prime Surgical, LLC : $40.5K total payments, HHI 288
- Alimera Sciences, Inc. (this company) : $791.8K total payments, HHI 287
- Bioventus LLC : $1.1M total payments, HHI 286
- Mayne Pharma Commercial LLC : $1.3M total payments, HHI 286
- IRRAS USA, Inc. : $15.1K total payments, HHI 285
- True North Surgical Inc : $27.3K total payments, HHI 281
- SK Life Science, Inc. : $2.1M total payments, HHI 281
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Alimera Sciences, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Alimera Sciences, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Alimera Sciences, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Grifols USA, LLC
$2.0M 23,281 recipients
Compare payment profiles
Ferring Pharmaceuticals Inc.
$2.0M 21,199 recipients
Compare payment profiles
CooperSurgical, Inc.
$1.9M 9,542 recipients
Compare payment profiles
PROCEPT BioRobotics Corporation
$1.9M 8,013 recipients
Compare payment profiles
Biohaven Pharmaceutical Holding Company Ltd.
$2.0M 0 recipients
Compare payment profiles
Put this to use
Alimera Sciences, Inc. ranks #452 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where Alimera Sciences, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Alimera Sciences, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.